Elsevier

Respiratory Medicine

Volume 102, Issue 2, February 2008, Pages 273-279
Respiratory Medicine

Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: A report of three cases

https://doi.org/10.1016/j.rmed.2007.09.001Get rights and content
Under an Elsevier user license
open archive

Summary

Background

To describe the possible role of oxaliplatin in worsening pre-existing interstitial lung disease.

Methods

After we encountered a patient with an interstitial lung disease who experienced a fatal progression of his pulmonary disease associated with oxaliplatin therapy, a computer-aided search was conducted to identify other similar patients. Twenty-six patients with various lung diseases who had received oxaliplatin therapy at Mayo Clinic in Rochester, MN from January 2000 to December 2006 were identified. Three of these patients had radiologic evidence of interstitial lung disease before undergoing oxaliplatin therapy. We examined the medical records and imaging studies of these three patients to further define their clinical presentation, radiological and functional characteristics, and clinical outcome.

Results

All three patients experienced symptomatic and radiologic worsening of their interstitial lung disease following oxaliplatin administration. One of these patients died from refractory respiratory failure; the remaining two patients stabilized after the discontinuation of oxaliplatin therapy and have since shown modest improvement in pulmonary symptoms and lung function. There were no other potential causes identified for the unexpected progression of their lung disease other than the temporal relationship to oxaliplatin therapy.

Conclusions

Treatment with oxaliplatin, in the setting of a pre-existing interstitial lung disease, may be associated with respiratory deterioration. It is unknown whether this is mediated by acceleration of the underlying parenchymal disease or by a superimposed acute lung injury caused by oxaliplatin.

Abbreviations

CRC
colorectal cancer
FOLFOX
chemotherapy regimen using oxaliplatin
leucovorin and fluorouracil
ILD
intersitial lung disease
HRCT
high resolution computed tomographic
PFT
pulmonary function tests
FVC
forced vital capacity
FEV1
forced expiratory volume in 1 s
TLC
total lung capacity
DLCO
diffusing capacity of carbon monoxide
CTD
connective tissue disease
CTA
computed tomographic angiography

Keywords

Interstitial lung disease
Colorectal cancer
Chemotherapy
Oxaliplatin
FOLFOX
Pulmonary fibrosis

Cited by (0)